Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Performance and Safety of Marial in GERD
NCT04130659Recruiting
- Sponsor
- Nekkar
- Start
- Aug 2019
- Primary completion
- Dec 2024
- Countries
- 2
01
Overview
Randomised, open-label trial (2 arms), sponsored by Nekkar. Primary endpoint: Total Gaviscon tablets consumption at 28 days. Started Aug 2019; status: recruiting.
Beyond the preview
Go deeper on NCT04130659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04130659.